Literature DB >> 8584993

Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment.

M Brännström1, J H Jansson, K Boman, T K Nilsson.   

Abstract

The aim of the present study was to test if long-term mortality could be predicted by endothelial derived haemostatic variables in a population with high morbidity due to thromboembolic disease. Plasma samples were drawn from 212 out-patients treated with oral anticoagulants, at the beginning of the study, and analyzed for mass concentration of tissue plasminogen activator (tPA) and its inhibitor (PAI-1), and von Willebrand factor. In the course of 3.8-year follow-up 45 patients died, including 38 vascular deaths. We found that all-cause mortality was significantly associated with increased levels of vWF and tPA. For vascular mortality there was a significant association with all three haemostatic variables (tPA, PAI-1, vWF). For vWF there was a 3-fold increase in total and vascular mortality in the highest quartile compared to the lowest quartile. There were 27 vascular deaths in the group of patients with a tPA-value above the median compared to 11 in those with a tPA below the median. In multivariate Cox regression analysis (including: age, sex, smoking habits, body mass index, diabetes mellitus, hypertension, tPA, PAI-1, and vWF), vWF and smoking were independently significantly associated with all-cause mortality, and tPA and age with vascular mortality. Endothelial derived haemostatic variables are predictors of total and vascular mortality in patients treated with oral anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584993

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy.

Authors:  Samuel G Johnson; Daniel M Witt; Thomas Delate; Melanie A Sadler
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

2.  Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; M D Cressman; D B Hunninghake; N L Fox; M L Terrin; J L Probstfield
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

3.  von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

4.  Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus.

Authors:  Türkan Acar; Yeşim Güzey Aras; Sıdıka Sinem Gül; Bilgehan Atilgan Acar
Journal:  Noro Psikiyatr Ars       Date:  2018-10-24       Impact factor: 1.339

5.  Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.

Authors:  Richard G Jung; Pouya Motazedian; F Daniel Ramirez; Trevor Simard; Pietro Di Santo; Sarah Visintini; Mohammad Ali Faraz; Alisha Labinaz; Young Jung; Benjamin Hibbert
Journal:  Thromb J       Date:  2018-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.